Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.
This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.
Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.
All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Data Collection Methods
- Participants' demographics will be collected at baseline using case record form.
- Laboratory tests include: at 3 clinical visits (Baseline, Day3, Day7 and Day 14 (optional if have cardiac manifestation) after 2nd dose of Pfizer COVID-19 vaccine) 2.1. Cardiac biomarker (Troponin-T, CK-MB) 2.2. Echocardiography 2.3. ECG (Electrocardiography)
After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
BAngkok, Thailand, 10400
- Faculty of Tropical Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Student age 13-18 who received 1st dose of pfizer COVID-19 vaccine from
- Kong thabbok upatham changkol kho so tho bo school
- Wachirathamsatit school
Beschreibung
Inclusion Criteria:
- Age 13-18 years old
- Both males and females
- Received 1st dose Pfizer COVID-19 vaccine injection
Exclusion Criteria:
- Unable to obtain written informed consent from the participants or their legal representatives
- History of cardiomyopathy, tuberculous pericarditis, and constrictive pericarditis
- Severe allergic reaction to COVID-19 vaccine
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at baseline
Zeitfenster: Day 0
|
cardiac manifestation defined as sinus tachycardia, hypertension at baseline
|
Day 0
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 3
Zeitfenster: Day 3
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 3
|
Day 3
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 7
Zeitfenster: Day 7
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 7
|
Day 7
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at baseline
Zeitfenster: Day 0
|
frequency (%) of participant with myocarditis at baseline
|
Day 0
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 3
Zeitfenster: Day 3
|
frequency (%) of participant with myocarditis at day 3
|
Day 3
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 7
Zeitfenster: Day 7
|
frequency (%) of participant with myocarditis at day 7
|
Day 7
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at baseline
Zeitfenster: Day 0
|
frequency (%) of participant with pericarditis at baseline
|
Day 0
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 3
Zeitfenster: Day 3
|
frequency (%) of participant with pericarditis at day 3
|
Day 3
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 7
Zeitfenster: Day 7
|
frequency (%) of participant with pericarditis at day 7
|
Day 7
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at baseline
Zeitfenster: Day 0
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline
|
Day 0
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 3
Zeitfenster: Day 3
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3
|
Day 3
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 7
Zeitfenster: Day 7
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7
|
Day 7
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Chayasin Mansanguan, M.D., Mahidol University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Cardiac and pfiizer
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Covid-19 Impfung
-
PfizerAktiv, nicht rekrutierendCOVID-19 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Covid-19 Impfungen | SARS-CoV-2-Infektion, COVID19 | COVID-19-Impfung | SARS-CoV-2-Infektion, COVID-19 | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionVereinigte Staaten
-
Shanghai Public Health Clinical CenterNoch keine Rekrutierung
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Abgeschlossen
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RekrutierungZustand nach COVID-19 | Nach COVID-19 | Post-COVID-19-Syndrom | Langes COVID-19-Syndrom | Zustand nach COVID-19 (PCC)Deutschland
-
PfizerRekrutierungErkrankungen der Atemwege | COVID-19 | Lungenentzündung | Lungenkrankheit | Coronavirus Krankheit 2019 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Infektionen der oberen Atemwege | Infektion der Atemwege | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionBelgien
-
ModeX Therapeutics, An OPKO Health CompanyRekrutierungCOVID 19 | COVID-19 (Prävention)Vereinigte Staaten
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRekrutierungErmüdung | Post-COVID-19-Syndrom | Zustand nach COVID-19 | Post-COVID-Syndrom | Lange COVID-19 | Lang-COVID | Post-COVID-ZustandKanada
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Aktiv, nicht rekrutierendCovid-19-TestverhaltenVereinigte Staaten
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...AbgeschlossenPostakute Folgen von COVID-19 | Zustand nach COVID-19 | Lang-COVID | Chronisches COVID-19-SyndromItalien
-
Yang I. PachankisAktiv, nicht rekrutierendCOVID-19 Atemwegsinfektion | COVID-19 Stresssyndrom | COVID-19-Impfstoff-Nebenwirkung | COVID-19-assoziierte Thromboembolie | COVID-19 Post-Intensive-Care-Syndrom | COVID-19-assoziierter SchlaganfallChina
Klinische Studien zur Diagnostic of ECG
-
York Teaching Hospitals NHS Foundation TrustRekrutierungMachbarkeitsstudien | Zentralvenöser Katheter | Führung durch das intrakavitäre Elektrokardiogramm | Point-of-Care-Ultraschall (POCUS)Vereinigtes Königreich
-
CHA UniversityRekrutierungMyokardinfarkt (MI) | Brustschmerzen schließen Myokardinfarkt ausSüdkorea
-
Consorci Sanitari de l'Alt Penedès i GarrafNoch keine RekrutierungAkute KrankheitSpanien
-
Universitair Ziekenhuis BrusselRekrutierungBrustschmerzen | Akute Koronarsyndrome (ACS)Belgien
-
National Defense Medical Center, TaiwanRekrutierungElektrokardiogramm | Wirtschaftlichkeitsanalyse | Künstliche Intelligenz (KI) | OMI - Okklusions -MyokardinfarktTaiwan
-
National Defense Medical Center, TaiwanAnmeldung auf EinladungHerzfehler | Ventrikuläre Dysfunktion, links | Künstliche Intelligenz | Asymptomatische Krankheiten | Kosten-Nutzen-Analyse | FrühdiagnoseTaiwan
-
William Beaumont HospitalsFoundation for Education and Research in Neurological EmergenciesAbgeschlossenTransitorische ischämische AttackeVereinigte Staaten
-
Fu Jen Catholic University HospitalRekrutierungEntwöhnung durch invasive mechanische BeatmungTaiwan
-
National Defense Medical Center, TaiwanRekrutierungBluthochdruck, Lungen | Künstliche Intelligenz (KI) | Künstliche Intelligenz (KI) in der DiagnoseTaiwan
-
Tri-Service General HospitalNoch keine Rekrutierung